CD206 Overview
Molecule Name
Macrophage mannose receptor 1
Synonyms
MMR,CD206,hMR,MRC1,CLEC13D,CLEC13DL,MRC1L1
Drug Development Progress
Drugs in Clinical Trials2
Approved Drugs1
Highest Development StageApproved
Target Synonym
C-type lectin domain family 13 member D，CLEC13D，Macrophage mannose receptor 1-like protein 1，hMR，Macrophage mannose receptor 1，C-type lectin domain family 13 member D-like，CLEC13DL，MRC1L1，MRC1，Mannose Receptor C-Type 1，Mannose Receptor， C Type 1-Like 1，Human Mannose Receptor，MMR，Mannose Receptor， C Type 1，CD206 Antigen，BA541I19.1，CD206
Background
Mrc1 is a conserved checkpoint mediator protein that transduces the replication stress signal to the downstream effector kinase. Mrc1 and its vertebrate homologue Claspin serve as a mediator for replication stress checkpoint signaling, receiving the signal from Mec1/Rad3/ATR sensor kinase and transmitting it to the effector Rad53/Cds1/Chk1 kinase. The loss of mrc1 checkpoint activity results in the aberrant activation of late/dormant origins in the presence of hydroxyurea. Tumor-associated macrophages (TAMs) expressing the multi-ligand endocytic receptor mannose receptor (CD206/MRC1) contribute to tumor immunosuppression, angiogenesis, metastasis, and relapse.
CD206 Product List
You Have Viewed 0 Of 0 Results
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| 68Ga-tilmanocept | Phase 3 Clinical | Navidea Biopharmaceuticals Inc | Atherosclerosis; Carcinoma, Endometrioid; Endometrial Neoplasms; Tuberculosis | Details | |
| 68GaNOTA-Anti-MMR-VHH2 | Phase 2 Clinical | Universitair Ziekenhuis Brussel | Atherosclerosis; Carcinoma, Non-Small-Cell Lung; Carotid Stenosis; Hodgkin Disease; Lymphohistiocytosis, Hemophagocytic; Lymphoma, Non-Hodgkin; Neoplasms; Sarcoidosis | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Technetium Tc 99m tilmanocept | NEO3-09 | Approved | University Of California | Lymphoseek Kit, Lymphoseek, Lymphoaim | United States | Solid tumours; Diagnostic agents; Breast Neoplasms; Melanoma; Carcinoma, Squamous Cell; Head and Neck Neoplasms | Cardinal Health 414 Llc | 2013-03-13 | Anus Neoplasms; Arthritis, Rheumatoid; Breast Neoplasms; Carcinoma, Squamous Cell; Central Nervous System Neoplasms; Colonic Neoplasms; Colorectal Neoplasms; Diagnostic agents; Endometrial Neoplasms; Head and Neck Neoplasms; HIV Infections; Liver Neoplasms; Melanoma; Metabolic Dysfunction-Associated Steatotic Liver Disease; Rectal Neoplasms; Sarcoidosis; Sarcoma, Kaposi; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Uterine Cervical Neoplasms | Details |